A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
about
Clinical experimentation with aerosol antibiotics: current and future methods of administration.Advances in device and formulation technologies for pulmonary drug delivery.Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and RifampicinSynergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.Inhalable Antitubercular Therapy Mediated by Locust Bean Gum Microparticles.Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates.Drug delivery for tuberculosis: is inhaled therapy the key to success?Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment.Spray Drying Strategies to Stop Tuberculosis
P2860
Q30448377-217E375D-F708-44B6-A5A9-A6E2CC201928Q33962567-99C09C69-70AC-4A40-8576-2E6F556001ACQ35352140-39F7F56C-0E3C-428F-8E19-CC56AD9CEA8CQ36653925-60A0AA57-2C98-4353-9CB2-15C56ADC510AQ37469403-10E1A7E9-E00D-4741-BB93-7C7B60F90BBEQ38236719-BA5915A3-93F1-4F2D-BB24-737FBB3D0FEFQ39725802-CEF15D58-5373-46C0-9778-D0280183BEDCQ42241235-33523488-3D31-4ED5-8076-91D77871A92EQ46650295-62083EE6-C6DE-4327-8924-D75B1EDB9AECQ47547837-B521C21E-C29A-4857-9AC6-3D4E493AFCE9Q47763488-97B8721B-37A9-4960-ADA6-D7DA45EC2328Q50074735-84906B79-DAAC-4F5A-90DB-7E3AEBFA140EQ59291746-D2CAF0E6-C67C-48B8-B394-0F807D7A3FC1
P2860
A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@ast
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@en
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@nl
type
label
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@ast
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@en
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@nl
prefLabel
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@ast
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@en
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@nl
P50
P1476
A novel dry powder inhalable f ...... e anti-tubercular antibiotics.
@en
P2093
Clive A Prestidge
John Gar Yan Chan
P304
P356
10.1016/J.EJPB.2012.08.007
P407
P577
2012-09-13T00:00:00Z